相似文献
1
Editorial on "heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial".
Neuro Oncol. 2014 Jan;16(2):169-70. doi: 10.1093/neuonc/not311.
2
Heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial.
Neuro Oncol. 2014 May;16(5):758-9. doi: 10.1093/neuonc/nou054. Epub 2014 Apr 10.
3
Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.
Neuro Oncol. 2014 Jan;16(2):274-9. doi: 10.1093/neuonc/not203. Epub 2013 Dec 12.
4
Is there a role for vaccine-based therapy in recurrent glioblastoma?
Neuro Oncol. 2014 May;16(5):757. doi: 10.1093/neuonc/nou031.
5
Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial.
JCI Insight. 2018 May 17;3(10). doi: 10.1172/jci.insight.99145.
6
Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents.
Expert Opin Biol Ther. 2014 Jul;14(7):955-67. doi: 10.1517/14712598.2014.902928. Epub 2014 Mar 26.
7
Heat shock proteins in glioblastomas.
Neurosurg Clin N Am. 2010 Jan;21(1):111-23. doi: 10.1016/j.nec.2009.09.002.
8
Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma.
J Transl Med. 2010 Jan 29;8:9. doi: 10.1186/1479-5876-8-9.
9
HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future.
Expert Rev Vaccines. 2009 Nov;8(11):1513-26. doi: 10.1586/erv.09.108.
10
[Peptide vaccination in glioblastoma].
Gan To Kagaku Ryoho. 2014 Jun;41(6):725-9.
引用本文的文献
1
A new weapon: the application of tumor vaccines based on extracellular exosomal heat shock proteins in immunotherapy.
Front Immunol. 2025 Jan 22;16:1510650. doi: 10.3389/fimmu.2025.1510650. eCollection 2025.
2
Is there a role for vaccine-based therapy in recurrent glioblastoma?
Neuro Oncol. 2014 May;16(5):757. doi: 10.1093/neuonc/nou031.
本文引用的文献
1
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.
Cancer Immunol Immunother. 2013 Jun;62(6):983-7. doi: 10.1007/s00262-013-1405-y. Epub 2013 Apr 17.
2
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
Blood. 2011 Sep 15;118(11):3003-12. doi: 10.1182/blood-2011-02-334565. Epub 2011 Jul 18.
3
Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.
Clin Cancer Res. 2011 Aug 15;17(16):5473-80. doi: 10.1158/1078-0432.CCR-11-0774. Epub 2011 Jul 7.
4
A novel method for volumetric MRI response assessment of enhancing brain tumors.
PLoS One. 2011 Jan 26;6(1):e16031. doi: 10.1371/journal.pone.0016031.
5
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Neuro Oncol. 2011 Mar;13(3):324-33. doi: 10.1093/neuonc/noq157. Epub 2010 Dec 10.
6
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
J Clin Oncol. 2010 Nov 1;28(31):4722-9. doi: 10.1200/JCO.2010.28.6963. Epub 2010 Oct 4.
7
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.
Mol Ther. 2010 Apr;18(4):666-8. doi: 10.1038/mt.2010.31.
8
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.
Mol Ther. 2010 Apr;18(4):843-51. doi: 10.1038/mt.2010.24. Epub 2010 Feb 23.
9
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
Cancer Res. 2006 Mar 15;66(6):3294-302. doi: 10.1158/0008-5472.CAN-05-3773.
10
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
J Clin Oncol. 2005 Sep 1;23(25):6043-53. doi: 10.1200/JCO.2005.06.205. Epub 2005 Aug 8.
Zotero 插件